Do medium‑vessel vasculitis lesions exhibit both lymphocytic and neutrophilic infiltration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medium Vessel Vasculitis: Inflammatory Infiltrate Patterns

Yes, medium vessel vasculitis exhibits both lymphocytic and neutrophilic infiltration, with the specific pattern depending on the disease subtype and stage of inflammation.

Histopathological Characteristics

The inflammatory infiltrate in medium vessel vasculitis varies by specific disease entity:

Polyarteritis Nodosa (PAN)

PAN demonstrates mixed-cell inflammatory infiltrates in the vessel wall with fibrinoid necrosis 1, 2. The guideline explicitly states that typical histologic findings include "mixed-cell inflammatory infiltrates in the vessel wall and fibrinoid necrosis, with an absence of granulomas and giant cells" 1. This mixed infiltrate includes both neutrophils and lymphocytes, though the predominant cell type may vary with disease activity.

Kawasaki Disease

The pathology of Kawasaki disease necrotizing vasculitis is most consistent with a primary role for monocytes/macrophages and T lymphocytes in the acute injury phase 3. This represents a more lymphocyte-predominant pattern compared to other medium vessel vasculitides.

Pathogenic Mechanisms and Cell Types

The different pathologic features reflect distinct pathogenic mechanisms:

  • Acute phase injury: Neutrophils and monocytes play the primary role in acute necrotizing injury in most medium vessel vasculitides 3
  • Chronic inflammation: Lymphocytic infiltration becomes more prominent in later stages
  • Disease-specific patterns: Medium vessel vasculitides often course with autoinflammatory features including neutrophilic infiltration, though lymphocytic components are also present 4

Clinical Implications for Diagnosis

When tissue biopsy is obtained (which is recommended when feasible for PAN diagnosis 1, 2), pathologists should:

  • Examine for mixed-cell inflammatory infiltrates rather than expecting a single cell type
  • Look for fibrinoid necrosis as a key diagnostic feature
  • Ensure adequate sampling including vessel wall architecture
  • Recognize that the inflammatory pattern may vary depending on disease stage and specific vasculitis subtype

The presence of both cell types is characteristic rather than contradictory, reflecting the complex immunopathology involving both innate (neutrophils) and adaptive (lymphocytes) immune responses in medium vessel vasculitis.

Related Questions

What other differential diagnoses should be considered in a child with several non‑blanching macules on the lower legs and focal popliteal fossa pain?
Can a biopsy demonstrating mild perivascular dermatitis with eosinophils be consistent with urticarial vasculitis?
What is the appropriate treatment for lymphocytic vasculitis?
What does a skin biopsy of the extremities showing a mild perivascular lymphocytic infiltrate with extravasated erythrocytes but no leukocytoclastic vasculitis indicate?
In a pediatric emergency department, how should a child with suspected vasculitis—presenting with fever and a new purpuric rash, persistent abdominal pain, arthralgia, edema, hypertension, hematuria, or neurologic signs—be evaluated and worked up?
What is the recommended starting dose and titration schedule of eplerenone for a patient with heart failure with reduced ejection fraction, based on estimated glomerular filtration rate and serum potassium levels?
What is the significance and recommended work‑up for an isolated alkaline phosphatase elevation of approximately 16 U/L above the upper reference limit with normal aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma‑glutamyl transferase (GGT)?
What is the risk of extrapyramidal motor side effects (EPMS) when using antipsychotic medications?
What is the risk of extrapyramidal motor disturbances associated with antipsychotic medications, and which agents have the lowest risk?
What is the risk of extrapyramidal symptoms (EPS) with cariprazine compared to other antipsychotic (neuroleptic) agents?
In hemorrhagic ascites, for how many red blood cells (RBCs) should one neutrophil (polymorphonuclear leukocyte, PMN) be subtracted?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.